These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35674074)

  • 1. Promoting exogenous repair in multiple sclerosis: myelin regeneration.
    Bezukladova S; Genchi A; Panina-Bordignon P; Martino G
    Curr Opin Neurol; 2022 Jun; 35(3):313-318. PubMed ID: 35674074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remyelinating strategies for the treatment of multiple sclerosis.
    Stangel M; Hartung HP
    Prog Neurobiol; 2002 Dec; 68(5):361-76. PubMed ID: 12531235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoting repair in multiple sclerosis: problems and prospects.
    Lubetzki C; Williams A; Stankoff B
    Curr Opin Neurol; 2005 Jun; 18(3):237-44. PubMed ID: 15891406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination.
    Keirstead HS; Blakemore WF
    Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches.
    Olsen JA; Akirav EM
    J Neurosci Res; 2015 May; 93(5):687-96. PubMed ID: 25287108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remyelinating Pharmacotherapies in Multiple Sclerosis.
    Bove RM; Green AJ
    Neurotherapeutics; 2017 Oct; 14(4):894-904. PubMed ID: 28948533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis.
    Motavaf M; Sadeghizadeh M; Javan M
    Cell Mol Neurobiol; 2017 Nov; 37(8):1335-1348. PubMed ID: 28224237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges.
    Murphy RP; Murphy KJ; Pickering M
    Bioengineered; 2013; 4(3):140-6. PubMed ID: 23147071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting remyelination in multiple sclerosis: current drugs and future prospects.
    Kremer D; Küry P; Dutta R
    Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repair strategies for multiple sclerosis: challenges, achievements and perspectives.
    Stankoff B; Jadasz JJ; Hartung HP; Küry P; Zalc B; Lubetzki C
    Curr Opin Neurol; 2016 Jun; 29(3):286-92. PubMed ID: 27035897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signalling pathways that inhibit the capacity of precursor cells for myelin repair.
    Sabo JK; Cate HS
    Int J Mol Sci; 2013 Jan; 14(1):1031-49. PubMed ID: 23296277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation stimulates remyelination in areas of chronic demyelination.
    Foote AK; Blakemore WF
    Brain; 2005 Mar; 128(Pt 3):528-39. PubMed ID: 15699059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current advancements in promoting remyelination in multiple sclerosis.
    Kremer D; Akkermann R; Küry P; Dutta R
    Mult Scler; 2019 Jan; 25(1):7-14. PubMed ID: 30270725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis.
    Jadasz JJ; Aigner L; Rivera FJ; Küry P
    Cell Tissue Res; 2012 Jul; 349(1):331-47. PubMed ID: 22322424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remyelination and multiple sclerosis: therapeutic approaches and challenges.
    Hartley MD; Altowaijri G; Bourdette D
    Curr Neurol Neurosci Rep; 2014 Oct; 14(10):485. PubMed ID: 25108747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous clues promoting remyelination in multiple sclerosis.
    Lubetzki C; Zalc B; Kremer D; Küry P
    Curr Opin Neurol; 2022 Jun; 35(3):307-312. PubMed ID: 35674073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting remyelination in multiple sclerosis.
    Cunniffe N; Coles A
    J Neurol; 2021 Jan; 268(1):30-44. PubMed ID: 31190170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of myelin replacement therapies in multiple sclerosis.
    Huang JK; Franklin RJ
    Prog Brain Res; 2012; 201():219-31. PubMed ID: 23186717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis.
    Gingele S; Stangel M
    Expert Opin Investig Drugs; 2020 Jun; 29(6):583-594. PubMed ID: 32348161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular senescence and failure of myelin repair in multiple sclerosis.
    Koutsoudaki PN; Papadopoulos D; Passias PG; Koutsoudaki P; Gorgoulis VG
    Mech Ageing Dev; 2020 Dec; 192():111366. PubMed ID: 32991921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.